X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

The U.S. Supreme Court gave something to both sides in a closely watched dispute over so-called "pay-for-delay" agreements between brand-name and generic drug manufacturers that put off the production of generics in return payments by brand-name patent holders.

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.